Viking Therapeutics: Stock at $34.95 after slight decline – analysts expect median price target of $93.60
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics closed on July 9, 2026 at $34.95, a decline of 0.43 percent from the previous day.
- 23 of 24 analysts recommend buying the stock, with only one assigning a Hold rating; there are no sell recommendations.
- The median price target among analysts is $93.60, representing theoretical upside potential of 168 percent.
- VK2809, the lead drug candidate in Phase IIb studies, targets the treatment of NASH and NAFLD.
- The RSI stood at 65.38 on July 8, following multiple days above 70 in June, suggesting a normalization of momentum.
Viking Therapeutics Inc. (VKTX) closed on July 9, 2026 at $34.95, recording a decline of $0.15 or 0.43 percent compared to the previous day's close of $35.10. The California-based biotechnology company's stock traded within a range of $34.30 to $35.35 during the trading day, with trading volume of approximately 23,600 shares.
Analysts see significant upside potential
The analyst community appears distinctly optimistic about Viking Therapeutics. Of 24 analysts covering the stock, 23 recommend buying the shares: one analyst assigns a "Strong Buy" rating, 22 assign a "Buy" rating, and only one assigns a neutral "Hold" rating. There are no sell recommendations ("Sell" or "Strong Sell") as of July 9, 2026.
The median price target among analysts is $93.60, with a median of $95.00. The price target range spans from $83.00 (lowest target) to $101.00 (highest target). If the median price target were reached, this would correspond to a theoretical upside potential of approximately 168 percent compared to the current price.
Technical indicators show solid momentum
The Relative Strength Index (RSI) – a momentum indicator that measures overbought or oversold conditions – stood at 65.38 for Viking Therapeutics on July 8, 2026. An RSI between 30 and 70 is considered neutral, with values above 70 indicating an overbought market condition. In preceding days, the RSI partly moved above 70: on July 7 it reached 74.67, on June 29 it reached 75.36, and on June 24 it reached 75.03, indicating strong upward momentum.
The recent cooling of the RSI to below 70 can be interpreted as a normalization after a phase of elevated buying activity, without the fundamental momentum being lost.
Pipeline focused on metabolic diseases
Viking Therapeutics is a clinical-stage biotech company developing novel therapies for metabolic and endocrine diseases. At the center of the research pipeline is VK2809, an orally administered, tissue- and receptor-selective agonist of the thyroid hormone receptor beta (TRβ). This drug candidate is currently undergoing Phase IIb studies for the treatment of non-alcoholic steatohepatitis (NASH) – a severe form of fatty liver disease with inflammation – as well as non-alcoholic fatty liver disease (NAFLD) in biopsy-confirmed patients.
Additional pipeline candidates include VK5211, an oral, non-steroidal selective androgen receptor modulator (SARM) currently in Phase II studies for patients recovering from non-elective hip fracture surgery. VK0612, an oral drug candidate for type 2 diabetes, is on the verge of entering Phase IIb studies. In addition, the company is developing VK0214, another oral drug candidate.
Classification for investors
The significant discrepancy between the current price ($34.95) and the median analyst price target ($93.60) reflects the typical valuation dynamics in the biotechnology sector. Companies in the clinical stage are frequently valued based on the success of their pipeline – positive study results or regulatory milestones can trigger substantial price movements, while setbacks carry corresponding risks.
The broad buy recommendation from analysts suggests confidence in the clinical programs, particularly in VK2809 for NASH and NAFLD. NASH is considered a growth market with high medical need, as only a few approved therapies currently exist. However, investors should consider the inherent risks of clinical development: Phase II studies are still far from market approval, and success is not guaranteed.
Trading data overview
- Closing price on July 9, 2026: $34.95
- Change: -$0.15 (-0.43 percent)
- Daily range: $34.30 to $35.35
- Trading volume: 23,556 shares
- RSI (July 8, 2026): 65.38
- Median price target: $93.60
- Analyst consensus: 1 Strong Buy, 22 Buy, 1 Hold
Viking Therapeutics is listed on a US stock exchange and trades in US dollars. For investors from the DACH region, currency risk should be considered when investing in USD-denominated securities. The company is headquartered in California and focuses on developing innovative therapeutic approaches for diseases that currently have limited treatment options.